Stay updated on Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial

Sign up to get notified when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Revision updated to v3.0.2; the Back to Top element was removed.
    Difference
    0.1%
    Check dated 2025-09-13T17:48:32.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-09-06T17:34:13.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The web page has been updated to include new drug information and resources related to specific types of lymphoma, while removing outdated references and certain drug classifications.
    Difference
    5%
    Check dated 2025-08-30T15:25:12.000Z thumbnail image
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.1%
    Check dated 2025-08-16T11:37:35.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.10 to v2.16.11.
    Difference
    0.1%
    Check dated 2025-08-09T06:46:58.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The web page has been updated to version v2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    0.9%
    Check dated 2025-08-02T02:51:38.000Z thumbnail image

Stay in the know with updates to Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin in HL and CD30+ PTCL Clinical Trial page.